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*Correspondingau
E-mail address: ta
http://dx.doi.org/10.10
1552-5260/ 2015 Th
creativecommons.org/neuropathology. Understanding amyloid deposition in DS can yield crucial information about disease
pathogenesis.
Methods: Forty-nine adults with DS aged 25–65 underwent positron emission tomography with
Pittsburgh compound–B (PIB). Regional PIB binding was assessed with respect to age, clinical,
and cognitive status.
Results: Abnormal PIB binding became evident from 39 years, first in striatum followed by rostral
prefrontal-cingulo-parietal regions, then caudal frontal, rostral temporal, primary sensorimotor and
occipital, and finally parahippocampal cortex, thalamus, and amygdala. PIB binding was related to
age, diagnostic status, and cognitive function.
Discussion: PIB binding in DS, first appearing in striatum, began around age 40 and was strongly
associated with dementia and cognitive decline. The absence of a substantial time lag between am-
yloid accumulation and cognitive decline contrasts to sporadic/familial AD and suggests this popu-
lation’s suitability for an amyloid primary prevention trial.
 2015 The Authors. Published by Elsevier Inc. on behalf of Alzheimer’s Association. This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Keywords: Alzheimer’s disease; Down syndrome; Amyloid; PIB; PET; Dementia; Striatum; Preclinical1. Introduction
Adults with Down syndrome (DS) invariably develop
senile plaques, composed of b-amyloid peptide (Ab), indis-
tinguishable from the histopathology of sporadic Alzheimer’s
disease (AD) [1,2], and have a high risk for the development
of early onset dementia [3] with estimated age-specifict no conflict of interest.
thor. Tel.:144-1223-746127; Fax:144-1223-746033.
337@medschl.cam.ac.uk
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licenses/by/4.0/).prevalence rates increasing from 20% to 50% in the fifties
to 30% to 75% in those aged .60 years [4]. Comparable
levels of amyloid can be observed in the brains of individuals
with DS without dementia to those seen in typically devel-
oping individuals with AD dementia [3]. It is now believed
that amyloid deposition in the typically developing popula-
tion with sporadic AD can occur more than a decade before
the clinical symptoms of dementia appear [5,6].
Similar to autosomal-dominant AD, people with DS are
genetically predisposed to increased amyloid accumulation;
in DS, this is the result of triplication of the amyloid’s Association. This is an open access article under the CCBY license (http://
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T. Annus et al. / Alzheimer’s & Dementia 12 (2016) 538-545 539precursor protein gene, located on chromosome 21. DS is
therefore a genetic example of Ab overproduction, making
it a highly complementary study group to the autosomally
inherited forms of AD that are presently being investigated
by the Dominantly Inherited Alzheimer Network (DIAN)
[7] or in the large single kindred of the Alzheimer Prevention
Initiative Autosomal Dominant Alzheimer’s Disease study
[8]. DS can yield crucial information about the generaliz-
ability of the pattern of cerebral amyloid accumulation
across different genetically determined forms of AD.
Furthermore, being a candidate group for amyloid primary
prevention trials—particularly because DS is more prevalent
than autosomally inherited AD—it is of critical importance
to first understand the behavior of amyloid in the DS popu-
lation so as to best optimize the timing of such studies.
Positron emission tomography (PET) imaging with li-
gands such as [11C]–Pittsburgh compound–B (PIB) enables
in vivo quantification and localization of fibrillar Ab
deposits [9]. Previous amyloid PET studies have reported
widespread cortical binding in people with DS after about
the age of 40 years [10–15] (Table 1). In younger individ-
uals, imaging has generally shown an absence of amyloid
binding, although some single isolated cases have been
reported with focal striatal binding [12–14]. These
previous studies have used large anatomic regions of
interest (ROI) in relatively small numbers of participants,
making a more fine-grained and systematic study of amyloid
accumulation across different brain areas highly desirable.
Moreover, with the exception of the pilot study [10] that
was the precursor to the present work, all previous amyloid
PET analyses in DS used standardized uptake value ratios of
static images; the present study utilized the more robust
method of calculating non–displaceable binding potential
(BPND) from dynamic image data. This report, therefore,
characterizes in detail the evolution of PIB binding in
cortical and subcortical regions of the DS brain.T
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2.1. Study design and participants
Forty-nine participants withDS aged 25–65 volunteered to
take part and successfully completed the neuropsychological
assessments and the imaging protocol of this study. Partici-
pants were identified via services for people with intellectual
disabilities in England and Scotland, through the Down Syn-
dromeAssociation or following responses to ourWeb site. All
received an easy-to-read information pack containing a leaflet
and a DVD (see: https://www.youtube.com/user/downsproje
ct/videos). Participants were screened for any contraindica-
tions to magnetic resonance imaging (MRI)/PET scanning.
All participants had previously received a clinical diagnosis
of DS based on having the characteristic phenotype. In addi-
tion, 33 participants had been karyotyped as part of a pervious
study, and all were confirmed to have full trisomy 21.
T. Annus et al. / Alzheimer’s & Dementia 12 (2016) 538-545540The study was approved by the National Research Ethics
Committee of East of England and the Administration of
Radioactive Substances Advisory Committee. Written con-
sent was obtained from all adults with DS with the capacity
to consent. For participants lacking the capacity to consent,
the procedures set out in the England and Wales Mental
Capacity Act (2005) were followed.2.2. Clinical assessments
All participants were assessed for dementia using the
Cambridge Examination for Mental Disorders of Older
people with Down’s Syndrome and Others with Intellectual
Disabilities (CAMDEX-DS) informant interview, designed
for diagnosing dementia in this population [16]. An expe-
rienced clinician (S.H.Z.), who was blind to the PIB status,
allocated each participant into the categories of: “stable
cognition,” “cognitive decline,” or “dementia.” “Dementia”
was diagnosed in accordance with the International Classi-
fication of Diseases-10 (ICD-10) criteria for dementia.
“Cognitive decline” diagnosis was given to participants
with evidence of functional decline in one or more
cognitive domains without fulfilling the full ICD-10
criteria for dementia. All participants, except three who
had serve dementia and were untestable, underwent the
cognitive function assessment component of the CAMDEX
schedule–CAMCOG.2.3. Imaging protocol2.3.1. PET using [11C]–PIB
[11C]–PIB PET data were acquired in three-dimensional
(3D) mode on a GEAdvance scanner (General ElectricMed-
ical Systems, Milwaukee, WI, USA). Before [11C]–PIB in-
jection, a 15-minute transmission scan using rotating 68Ge
rod sources was acquired to correct for photon attenuation.
[11C]–PIB was produced with high radiochemical purity
(.95%) and specific activity (.150 GBq/mmol). [11C]–
PIB was injected as a bolus (median5 545 MBq, interquar-
tile range 5 465–576 MBq) through an antecubital venous
catheter, and data were acquired for 90 min after injection
in 58 frames (18! 5 seconds, 6! 15 seconds, 10! 30 sec-
onds, 7! 1 minute, 4! 2.5 minutes, and 13! 5 minutes).
For each frame, sinogram data were reconstructed using the
PROMIS 3D filtered back projection algorithm [17] into a
128 ! 128 ! 35 image array with a voxel size of
2.34 ! 2.34 ! 4.25 mm3. Corrections were applied for
random coincidences, dead time, normalization, scatter,
attenuation, and sensitivity. In keeping with the pilot, feasi-
bility work done in the planning phase of this study [18], all
participants with DS tolerated the 90-minute scan without
major head movement and mostly fell asleep during the
acquisition. All scans were also visually inspected with
none showing degradation of images due to motion. All sub-
jects also underwent volumetric MRI scanning to facilitateROI analysis, the details of which are included in the
Supplemental Material.2.4. Imaging analysis2.4.1. ROI analysis
Regional PIB analysis utilized amanually improved Brod-
mann atlas (based on that available in MRIcron) in Colin27
space. Several very small Brodmann areas were collapsed
into larger regions to avoid ROIs of subvoxel resolution (for
a list of collapsed Brodmann areas, please refer to
Supplementary Table 1). The amended Brodmann atlas was
standardized to the study-wise space in two steps: (1) compo-
sition of affine and nonlinear transformations, followed by (2)
nearest-neighbor interpolation. Transforms were computed
via deformable registration of skull-stripped study-wise and
Colin27 templates using the Greedy SyN mapping approach
including Gaussian regularization (sigma 5 3 mm) and
driven uniquely by the cross-correlation metric (window
radius 5 4 mm) and gradient step length of 0.15 for
100! 100! 80 multi-resolution iterations. Skull-stripping
was performedusing an iterative routine available in advanced
normalization tools (ANTs).
Deep brain ROIs were calculated from the study-specific
template using a fully automated approach—FIRST, avail-
able from the FMRIB software library (http://fsl.fmrib.ox.
ac.uk/fsl/fslwiki/FIRST). The following subcortical struc-
tures were included: striatum (caudate nucleus and puta-
men), amygdala, thalamus, and hippocampus. The nucleus
accumbens, brain stem, and globus pallidus were excluded
from the analysis due to small size, poor FIRST segmenta-
tion, and high frequency of calcified lesions, a known feature
in DS [19], respectively.
2.4.2. Extracting regional PIB binding data
Dynamic PET images were realigned with statistical
parametric mapping (SPM) and then averaged. The resultant
mean images were rigidly coregistered with ANTs to their
corresponding bias-corrected magnetisation–prepared, rapid
gradient–echo MRI (MPRAGE) volume. Compositions of
concatenated transformations (from PET native space to
study template) were calculated and applied to PET images
followed by linear interpolation. The intersection of the stan-
dardized Brodmann atlas with a 65% gray-matter proba-
bility mask (derived from the study template SPM
segmentation) was applied to spatially normalized PET im-
ages to extract time-activity curves (TAC) for each region,
which were then subjected to reference tissue input kinetic
modeling. The reference tissue ROI was the superior cere-
bellar region constrained to 90% gray-matter probability.
To ameliorate partial volume error from cerebrospinal fluid
(CSF) contamination of the ROI signal, Gaussian smoothing
was applied to the CSF segment to approximate the PET
spatial resolution and hence each ROI TAC (including that
of the reference tissue) was divided by 1–fCSF, where fCSF
T. Annus et al. / Alzheimer’s & Dementia 12 (2016) 538-545 541is the average CSF fraction in the ROI. For each ROI, BPND
was obtained using a basis function implementation of the
simplified reference tissue model (RPM) [20]. Determina-
tion of BPND with RPM used 100 basis functions with
0.04 q3 0.6 min21.2.5. Establishing the stages of abnormal PIB binding
For each ROI, abnormal PIB binding was assigned to a
region in the PIB-positive group with a BPND exceeding
two standard deviations of the same region’s mean BPND
in the PIB-negative group. Grouping of “positive” and
“negative” was based on the striatal BPND as discussed in
the following. To understand the spread of amyloid in the
brain, a cumulative rank ordering of abnormal regions was
created. This was done by creating a new regional stage
only when participants that had abnormal BPND for that
given stage had abnormal BPND for the preceding stage.
The ranking table of raw data together with a detailed
description of the methodology is available in
Supplementary Fig. 1. In addition to the ranking of ROIs,
data were also analyzed as mean cortical BPND for the entire
cortex; this analysis also included 10 healthy, age-matched
(mean 5 36.4, range, 24–52), non–DS controls to ensure
that what was deemed to be PIB-negative in the DS popula-
tion would also consider negative in the general population.Fig. 2. Age has a strong nonlinear relationship with (A) the number of total
regions with abnormal BPND (R
2 5 0.735) and (B) mean cortical BPND2.6. Statistical analysis
Regional BPND data showed a non–Gaussian distribution,
when analyzed for normality with the Shapiro-Wilk test (all
P , .01). Therefore, nonparametric tests in SPSS Statistics
21.0 (IBM, Corp.) were used for all statistical analyses. In-
dependent group and correlation analyses were conducted
usingMann-Whitney U test and Kendall’s tau–b test, respec-
tively. To facilitate comparisons across studies, effect size
estimate, r, was calculated from the statistic’s z-score and re-
ported for all independent group analyses. The relationship
between categorical variables was compared using chi-
square or Fisher exact test for comparisons with expectedFig. 1. A scatter-plot representation of striatal non–displaceable binding
potential for all participants, demonstrating the presence of two distinguish-
able populations. Classification of the two groups—PIB-positive and PIB-
negative—was based onvisual inspection of the data presented in this figure.
Abbreviations: PIB, Pittsburgh compound–B; BPND, non–displaceable
binding potential.frequencies below five. Plots were generated in GraphPad
Prism 5.04 (GraphPad Software, Inc.), and the sigmoidal
curve in Fig. 2 was fitted using a four-parameter logistic
model. A significance level of .05 was used for all inferences
with results reported as median together with interquartile
range, unless otherwise stated.3. Results
3.1. Defining PIB-positive and PIB-negative groups
The distribution of striatal BPND in all participants
revealed a bimodal distribution (Fig. 1), a phenomenon not
apparent for other regions (data not presented). Furthermore,
no individual devoid of striatal binding (i.e. in the(R2 5 0.728) in adults with DS. The youngest participant with abnormal
PIB binding was 39 years old, and all individuals in this study aged
.49 years displayed both abnormal subcortical and cortical PIB binding
irrespective of their dementia status. The majority in the cognitively stable
group (26 of the 33) had normal PIB binding; the other seven participants
showed various levels of PIB binding. Themajority (five of six) in the cogni-
tive decline group had increased binding in 16 or more regions, whereas one
participant in the cognitive decline and two in the dementia group had no
evidence of increased PIB binding. Regions with abnormal/increased bind-
ing are defined as those with a BPND value that exceeds two standard
deviations of themean BPND for that given region in the PIB-negative group.
(B) also includes BPND data of ten age-matched (mean 5 36.4; range,
24–52 years), non–DS controls that act as “true control” of negative PIB
binding, demonstrating that the PIB binding observed in the PIB-negative
DS group is no different to what is considered negative in the typically
developing population. Please note that some data points in (A) are overlap-
ped if two or more participants of the same age had the same number of
abnormal PIB-binding regions. Abbreviations: BPND, non–displaceable
binding potential; DS, Down syndrome; PIB, Pittsburgh compound–B.
T. Annus et al. / Alzheimer’s & Dementia 12 (2016) 538-545542PIB-negative group) showed evidence of abnormal BPND in
any other brain region (i.e. striatal binding was always
present if any other brain region demonstrated binding).
Therefore, subsequent analyses were conducted in two
groups, PIB-negative (n 5 29, open circles in Fig. 1) and
PIB-positive group (n 5 20, closed circles in Fig. 1), based
on the bimodal distribution of striatal BPND.Fig. 3. A schematic brain map of numbered Brodmann areas and subcor-
tical regions of interest colored according to the PIB staging model, where
shade 1 denotes the area affected first (i.e. the striatum) and shade 9 the area
affected latest (the amygdala). Abbreviations: thal, thalamus; amy, amyg-
dala; PIB, Pittsburgh compound–B.3.2. The relationship between PIB binding, age, and
diagnostic status
Demographic details of the study cohort are listed in
Table 2. A strong sigmoidal relationship was apparent be-
tween age and the number of regions with abnormal binding,
the latter increasing exponentially from about 40 years until
plateau was reached at approximately 55 years (Fig. 2A).
The same steep sigmoidal relationship was observed when
mean cortical BPND was plotted as a continuous variable
against age (Fig. 2B). This analysis also showed that “nega-
tive” cortical binding in the DS population was no different
to what is considered negative in the typically developing,
non–DS subjects.
A positive correlation with age and the number of regions
demonstrating abnormal PIB binding was evident for the
whole cohort (Kendall’s correlation coefficient tau
(49)5 0.627, P, .001). Diagnostic status was significantly
correlated with the spatial extent of amyloid deposition
(Kendall’s correlation coefficient tau (49) 5 0.582,
P , .001), participants with stable cognition (median 5 0
abnormal binding regions) exhibited PIB binding in signifi-
cantly fewer regions in comparison with thosewith dementia
(median 5 29 abnormal binding regions, Mann-Whitney U
(43)5 280.50, P, .001, r5 0.60) and those with cognitive
decline (median 5 27 abnormal binding regions, Mann-
Whitney U (39) 5 167.50, P , .01, r 5 0.52). There was
no significant difference in the number of abnormal binding
regions between participants with cognitive decline and
those with dementia (Mann-Whitney U (16) 5 39.50, ns,
r 5 0.26). A significant negative correlation was found be-
tween CAMCOG scores and the number of abnormalTable 2
Study demographics
Demographics
PIB-positive
(n 5 20)
PIB-negative
(n 5 29)
P value
(effect size, r)
Age, y 50 (39–65) 36 (25–48) ,.0001* (20.72)
Female 8 (40) 15 (52) .419y
Dementia 8 (40) 2 (7) ,.01z
Cognitive decline 5 (25) 1 (3) ,.05z
CAMCOG score
(max 109)
74 (17–95) 76 (38–102) .406* (0.12)
Abbreviation: PIB, Pittsburgh compound–B.
NOTE. Data are shown as median (absolute range) or number (%). All
participants had mild-to-moderate learning disability.
*Mann-Whitney U test.
yChi-squared test.
zFisher exact test.binding regions in the PIB-positive group (Kendall’s correla-
tion coefficient t (16) 5 20.424, P , .05).3.3. Stages of amyloid deposition
The cumulative ranking of abnormal regional PIB bind-
ing is shown in Fig. 3 (for the ranking using raw BPND
data, please refer to Supplementary Fig. 1). Nine stages of
binding were identified. The striatum was the first region
to show increased PIB binding, as 100% of individuals
who were PIB-positive in one or more extrastriatal region(s)
also had binding in the striatum; the second stage involved
dorsal prefrontal cortex and anterior cingulate cortex; the
third stage ventral prefrontal cortex and areas of the parietal
lobe, including the superior parietal lobule; the fourth stage
involved most of the lateral temporal cortex and the rest of
the parietal lobe; the fifth primary sensory and motor areas;
the sixth stage identified abnormal PIB binding in the asso-
ciative visual cortex, premotor cortex, and the rest of the
temporal lobe. Stage 7 was associated with amyloid in the
occipital lobe. The eighth stage of the progression model
involved the thalamus and parahippocampal cortex,
T. Annus et al. / Alzheimer’s & Dementia 12 (2016) 538-545 543followed by the amygdala in the final stage 9. No partici-
pants exhibited abnormal PIB binding in the hippocampus.4. Discussion
This study found that PIB binding in the brains of adults
with DS becomes evident from around age 40 years and in-
creases in spatial extent in an age-dependent manner. The first
brain region to become PIB-positive was the striatum,
followed by PIB binding in the rostral prefrontal-cingulo-
parietal regions, then caudal frontal, rostral temporal, primary
sensorimotor and occipital, and finally mediotemporal
regions and the rest of the basal ganglia. A critical finding
of the study was that evidence of abnormal PIB binding
was strongly associated with a clinical diagnosis of “demen-
tia” or “cognitive decline” (65%of cases) without evidence of
a substantial time window between the development of
abnormal PIB binding and cognitive decline. This appears
to represent a contrast to both sporadic AD and familial
AD, where evidence suggests a latency of many years
between amyloid accumulation and clinical dementia
[5,6,21]. However, the lack of time lag between PIB
positivity and cognitive decline in DS might be partially
due to PIB not detecting the nonneuritic forms of amyloid
plaques that are present in abundance in the DS cortex from
as early as age 12 years [22]. Even so, the present study
and previous investigations in sporadic and familial AD
were conducted using similar methods of in vivo amyloid
PET imaging, and thus have yielded findings of the estimated
time course from amyloid deposition to cognitive decline that
are comparable with the results of the present study.
The distribution of PIB binding in DS as shown for this
study is congruent with previous findings in the DIAN cohort
[21]and in sporadic AD [9]. This combined evidence sug-
gests that amyloid accumulation, once established, is likely
to be similar across different forms of AD and further sup-
ports the generalizability of the amyloid PET findings. There
might, however, be a discrepancy in the temporal evolution
of PIB binding between sporadic and genetic AD with
respect to early striatal binding. Striatal binding was the
earliest feature in this series and was universal if participants
had abnormal binding in any other brain region; this repli-
cates findings in both DS [12–14] and in familial forms of
AD (amyloid precursor protein and presenilin-1 mutations
carriers) [23–26]. In sporadic AD, pathologic studies
[27,28] and amyloid imaging [29] have demonstrated exten-
sive amyloid deposition in the striatum of virtually all
demented AD patients. Striatal amyloid together with
cortical amyloid has been also reported in cognitively
normal presymptomatic individuals [29,30]. Studies
directly examining whether there may be a “striatum-only”
earlier phase of PIB binding in sporadic AD are, however,
lacking at present. In general, pathologic studies in
sporadic disease have tended to suggest that striatal
amyloid is not a very early feature [27,28], although this
region traditionally has not been intensively researched inAD. The current findings combined with those in familial
AD suggest that a pathologic re-examination of this region
is justified. Turning to the nature of striatal amyloid, past
studies have shown that striatal plaques in sporadic AD are
mainly of nonneuritic type [31,32], although cored and
neuritic plaques have also been reported [30,33]. Post
mortem studies in DS [31,34] and in familial AD [35]
have also identified mainly nonneuritic striatal amyloid
with rare reports of neuritic plaques only in cases with severe
cortical amyloidosis. PIB is known to bind to nonneuritic—
as well as neuritic and cored—plaques [36]; therefore, the
findings in this DS cohort are compatible with striatal amy-
loid being nonneuritic in nature. Immunohistochemistry
studies have shown that striatal plaques are predominantly,
or entirely, composed of Ab1–42 and Ab1–43 [31,34].
Familial forms of AD and DS share overproduction of
amyloid as the proposed mechanism of amyloid deposition
[37], whereas decreased clearance might be more significant
in sporadic AD [38]. Therefore, it might be that the cellular
milieu of the striatum is particularly vulnerable to early am-
yloid accumulation under the conditions of overproduction.
A strength of the present study was that it showed the
relative change in amyloid binding across the adult life
span (from 25 to 65 years) in an ultra high-risk population
for AD. As expected, higher PIB binding levels were
observed in participants with higher age, lower cognitive
performance on neuropsychological assessment, and in
those with a diagnosis of dementia. The data showed that
although comparison of the number of regions with
increased PIB binding tended to separate people with de-
mentia from thosewith stable cognition, it was unable to suf-
ficiently distinguish between individuals with cognitive
decline and those with dementia. This is consistent with a
wealth of evidence that plaque pathology has already
reached a plateau with the first signs of cognitive decline
and then remains relatively stable throughout the duration
of the clinical disease [6]. Interestingly, in contrast to such
findings, some participants in this study had cognitive
decline or dementia without having reached the plateau dis-
tribution of PIB binding (Fig. 2) possibly related to reduced
cognitive reserve in the DS population. Two participants
diagnosed with dementia in the cohort showed no PIB bind-
ing. Similar findings have been reported by the Alzheimer’s
Disease Neuroimaging Initiative PET core, showing that
10%–20% of their clinically diagnosed AD subjects are
PIB-negative [39] with the suggestion that these could repre-
sent the presence of non-AD dementia [40]. Although the
two apparently demented PIB-negative subjects in the
present series might also represent non-AD pathology, it is
probably more likely a reflection of the occasional difficulty
in making an accurate early dementia diagnosis in the DS
population. This is particularly exacerbated by the presence
of underlying intellectual disability, frequent lack of infor-
mation about individual’s premorbid level of functioning,
and difficulties in communication, and therefore heavy reli-
ance on informant opinion [41].
T. Annus et al. / Alzheimer’s & Dementia 12 (2016) 538-545544This study has a number of limitations. A sequence of
amyloid deposition in the DS population is characterized
from a cross-sectional data set. Although this approach is
the norm in post mortem–based pathologic staging systems,
a longitudinal study in this population is essential to validate
the reported findings. Furthermore, diagnosing dementia in
people with intellectual disabilities (including DS) is a
particular challenge with an acknowledged risk of uncer-
tainty [41]; albeit to a lesser degree, this is also true, howev-
er, in sporadic AD. The CAMDEX–DS has been validated as
a reliable tool for assessing clinical dementia in people with
DS [16], which in combination with an amyloid PET scan
should increase the confidence of dementia being of Alz-
heimer’s type in DS.
Several trials to date, aimed at preventing cognitive
decline in AD with anti-amyloid therapies, have been unsuc-
cessful [42]. These studies have all targeted patients with an
established amyloidosis. Primary prevention trials, in
contrast, are arguably the ultimate test of anti-amyloid ther-
apies—if such strategies were ever to work, then preventing
amyloid from ever accumulating would surely be more
effective than its removal. Primary prevention trials are not
feasible in sporadic disease, and even in individuals with
autosomal dominant mutations, the long latency between
amyloid accumulation and cognitive decline would mean a
primary prevention trial would have to run for many years,
which would be costly and logistically difficult. The present
study, however, suggests that DS is ideal for a primary pre-
vention study for two reasons. First, it demonstrated that
conversion from amyloid negative to positive occurs within
a fairly narrow age window in the early forties. Second, the
data (Fig. 2) indicate that there is a relatively short latency
between amyloid accumulation and cognitive decline in
DS—presumably related to reduced cognitive reserve as a
consequence of the developmental disorder. There is also
the recruitment advantage of DS being far more common
than autosomal dominant forms of AD. The impact of a pri-
mary prevention trial in DS could be immense. If successful,
it could eradicate dementia in DS. Moreover, the insights
that such a trial could yield, whether positive or negative,
would likely have a profound influence on the prioritization
of anti-Alzheimer strategies more broadly.Acknowledgments
The research team thank the PET imaging technologist, MR
radiographers, technicians, and radiochemists at the Wolf-
son Brain Imaging Centre, together with clinicians for their
help in acquiring the data reported in this article. The authors
particularly thank all participants with Down syndrome,
their families, and carers for their time and commitment to
this research. Furthermore, the research team extend their
gratitude to K€atlin Liiv for the creation of the amyloid stag-
ing brain illustration.
This research was generously supported by a grant from the
Medical Research Council (grant ID number: 98480).Additional support came from the NIHR Cambridge
Biomedical Research Centre, the NIHR Collaborations in
Leadership for Applied Health Research and Care
(CLAHRC) for the East of England, the NIHR Cambridge
Dementia Biomedical Research Unit, the Down Syndrome
Association, and the Health Foundation.
The sponsors of the study had no role in the design and
conduct of the study; collection, management, analysis and
interpretation of the data; writing and review of the report;
and decision to submit the article for publication.
Supplementary data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.jalz.2015.07.490.RESEARCH IN CONTEXT
1. Systematic review: Literature review using PubMed
identified six cross-sectional investigations of amy-
loid in people with Down syndrome (DS), reporting
amyloid in frontal, parietal, and temporal lobes,
cingulate cortex, striatum and thalamus. However,
these reports are limited in anatomic detail and have
not assessed the temporal evolution of amyloid bind-
ing in DS, thus leaving a gap in the knowledge that
would be of great benefit in the development of pre-
vention strategies for Alzheimer’s disease.
2. Interpretation: Our data show that amyloid accumu-
lation begins in the striatum in people with DS and
progresses in a predictable manner. A key finding
was the narrow window between amyloid accumula-
tion and cognitive decline suggesting that a primary
prevention anti-amyloid trial in DS could be feasible.
3. Future directions: Further studies are needed to vali-
date this amyloid accumulation model in a larger
data set and to establish its potential as a biomarker
and tool for assessing the efficacy of amyloid-
targeting agents.References
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